ArticleJournal of neurovirology2008
Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy.
Article in Journal of neurovirology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Up-to-date knowledge about the association between multiple sclerosis and the reactivation of human endogenous retrovirus infections.Journal of neurology · 2018Pooled it
- Trial
- Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.PloS one · 2011Trial
- The relationship between HERVs and exogenous viral infections: A focus on the value of HERVs in disease prediction and treatment.Virulence · 2025Review
- The Role of Microorganisms in the Etiopathogenesis of Demyelinating Diseases.Life (Basel, Switzerland) · 2023Review
- Endogenous Retroviruses as Modulators of Innate Immunity.Pathogens (Basel, Switzerland) · 2023Review
- HSV-1 and Endogenous Retroviruses as Risk Factors in Demyelination.International journal of molecular sciences · 2021Review
- Human Endogenous Retrovirus as Therapeutic Targets in Neurologic Disease.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Endogenous Retroviruses in Nervous System Disorders.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis.Frontiers in immunology · 2021Article
- Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World.Frontiers in immunology · 2021Review
- Expression of HERV Genes as Possible Biomarker and Target in Neurodegenerative Diseases.International journal of molecular sciences · 2019Review
- Do Human Endogenous Retroviruses Contribute to Multiple Sclerosis, and if So, How?Molecular neurobiology · 2019Review
- Integrative analysis of Multiple Sclerosis using a systems biology approach.Scientific reports · 2018Article
- Human Endogenous Retroviruses in Neurological Diseases.Trends in molecular medicine · 2018Review
- Review
- Treatment against human endogenous retrovirus: a possible personalized medicine approach for multiple sclerosis.Molecular diagnosis & therapy · 2015Article
- HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV.Retrovirology · 2014Article
- Human endogenous retroviruses and the nervous system.Handbook of clinical neurology · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors performed a longitudinal evaluation of multiple sclerosis (MS) patients, during 1 year of therapy with interferon-beta (IFN-beta), by clinical examination and detection of presence in the blood and viral load of MS-associated retrovirus (MSRV), by MSRVenv-specific, fully quantitative, real time reverse transcriptase-polymerase chain reaction (RT-PCR). MSRV load in the blood was directly related to MS duration and fell below detection limits within 3 months of IFN therapy; one patient had strong progression, accompanied by total MSRV rescue. These findings suggest that evaluation of plasmatic MSRV could be considered the first prognostic marker for the individual patient, to monitor disease progression and therapy outcome.
Indexed as
Identifiers
18300077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.